Drug Trial News

RSS

Tolero granted exclusive global rights to commercialize MannKind's novel BTK compounds

Tolero Pharmaceuticals and MannKind Corporation today announced a license agreement granting Tolero exclusive worldwide rights to develop and commercialize compounds from MannKind's novel BTK (Bruton's tyrosine kinase) program, which are currently being developed for the treatment of hematological malignancies and inflammatory diseases.

30 Apr 2012

Pharmanest commences SHACT Phase I pharmacokinetic study

Karolinska Development: Pharmanest AB today announced that the first patient has been dosed in an open label pharmacokinetic study with its drug candidate SHACT, a product developed for pain relief in connection with intrauterine device (IUD) insertion.

30 Apr 2012

Only few clinical trials are being conducted to test drugs in pediatric patients

Although children are more likely than adults to suffer from many diseases, few clinical trials are being conducted to test drugs in pediatric patients, according to a study to be presented Saturday, April 28, at the Pediatric Academic Societies (PAS) annual meeting in Boston.

30 Apr 2012

New URMC trial to evaluate carvedilol for high blood pressure

Researchers at the University of Rochester Medical Center are testing whether different doses of an established blood pressure medication can provide the same benefits as a standard dose in people with mild hypertension, possibly with fewer side effects and at a lower cost. The newly launched clinical trial, funded with a $1.9 million grant from the National Heart Lung and Blood Institute, is the first of its kind in the United States.

27 Apr 2012

Positive top-line results from Shire’s Vyvanse Phase 2 study on binge eating disorder

Shire plc, the global specialty biopharmaceutical company, today announced positive top-line results from a Phase 2 study to evaluate the safety and efficacy of Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) in adults with binge eating disorder.

27 Apr 2012

CytRx commences INNO-206 Phase 2 clinical trial for pancreatic cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 2 clinical trial evaluating the preliminary efficacy and safety of INNO-206 in patients with advanced pancreatic ductual adenocarcinomas (PDA) who have progressed after receiving two prior therapies.

26 Apr 2012

First-ever study to evaluate effects of interaction between metamphetamines and Ibudilast

John W. Tsuang, M.D., principal investigator at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), in conjunction with Steven J. Shoptaw, Ph.D., from the UCLA Department of Family Medicine, is spearheading a Phase I clinical safety trial that for the first time examines the effects of Ibudilast when administered with metamphetamine (MA), an addictive stimulant that is closely related to amphetamine.

26 Apr 2012

ASIA honors SCI researchers with 2012 Apple Award

American Spinal Injury Association (ASIA) has awarded its 2012 Apple Award to the article by Mark Nash, PhD, et al, entitled, "Safety, tolerance, and efficacy of extended-release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomized multicenter controlled trial."

26 Apr 2012

Daily ART safe and effective in preventing mother-to-child HIV transmission

In early results of a large-scale randomized study published in 2010 and led by researchers from the University of North Carolina at Chapel Hill, giving daily antiretroviral drugs (ART) to HIV-infected moms or their breastfeeding babies for 28 weeks proved safe and effective for preventing mother-to-child HIV transmission through breast milk.

26 Apr 2012

Clinical and Translational Science Institute-Children's National awards pilot grant to GW researchers

GW researchers in the School of Medicine, Jeffrey M. Bethony, Ph.D., Associate Professor of Microbiology, Immunology, and Tropical Medicine and David Diemert, M.D., FRCP(C), Associate Research Professor of Microbiology, Immunology, and Tropical Medicine and Director of Clinical Trials for the Sabin Vaccine Institute's Product Development Partnership (PDP), have been awarded a Pilot Grant from the Clinical and Translational Science Institute-Children's National.

25 Apr 2012

Positive results from Repligen's RG3039 Phase 1 study for spinal muscular atrophy

Repligen Corporation today announced positive results from a Phase 1 study to evaluate the pharmacokinetic (PK) and safety profile of RG3039, a novel small molecule drug candidate for the potential treatment of spinal muscular atrophy (SMA).

25 Apr 2012

Omega-3 supplements do not improve diastolic function in older adults

Over the past three decades, researchers have firmly established that the omega-3 fatty acids in fish oil, including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have healthy effects on the heart. Omega-3 fatty acids seem to help both in preventing cardiovascular disease as well as in preventing future heart attacks, strokes, and other adverse events in people who have established cardiovascular disease.

25 Apr 2012

S-equol effective in reducing menopausal hot flashes, muscle and joint pain among U.S. women

A dose of 10 milligrams (mg) daily of S-equol delivered via a newly developed fermented soy germ-based nutritional supplement is as effective as a standard dose of soy isoflavones at reducing hot flash frequency significantly and is even more effective for relieving muscle and joint pain, according to a peer-reviewed study in US postmenopausal women published in the June Journal of Women's Health, available now as a Fast Track article online ahead of print.

25 Apr 2012

Clinical trial to evaluate IGF-1 in children with SHANK3 deficiency

In an important test of one of the first drugs to target core symptoms of autism, researchers at Mount Sinai School of Medicine are undertaking a pilot clinical trial to evaluate insulin-like growth factor (IGF-1) in children who have SHANK3 deficiency (also known as 22q13 Deletion Syndrome or Phelan-McDermid Syndrome), a known cause of autism spectrum disorder (ASD).

25 Apr 2012

Biogen Idec announces positive data from oral BG-12 second Phase 3 trial on RRMS

Today Biogen Idec announced that detailed positive data from CONFIRM, the second Phase 3 clinical trial of oral BG-12 (dimethyl fumarate) in people with relapsing-remitting multiple sclerosis (RRMS), will be presented in three platform presentations at the 64th Annual Meeting of the American Academy of Neurology (AAN) in New Orleans.

25 Apr 2012

Protein blend intake following resistance exercise may build muscles

Today at Experimental Biology 2012, Dr. Blake Rasmussen and colleagues presented a new and first-of-its-kind clinical study: "Effect of Protein Blend vs. Whey Protein Ingestion on Muscle Protein Synthesis Following Resistance Exercise." The results of this study suggest that a protein blend (combination of soy, whey and casein) may be best to consume post-workout for building muscle. Specifically, the blend of proteins in this study showed an increase in a person's "anabolic window."

24 Apr 2012

Gabapentin drug helps people to quit cannabis

Scientists at The Scripps Research Institute have found clinical evidence that the drug gabapentin, currently on the market to treat neuropathic pain and epilepsy, helps people to quit smoking marijuana.

24 Apr 2012

R-Tech Ueno completes RK-023 phase I study on hypotrichosis of the eyelashes

R-Tech Ueno is pleased to announce the completion of a phase I clinical study of RK-023, a new compound that is being developed for the treatment of hypotrichosis of the eyelashes.

24 Apr 2012

Medgenics seeks FDA Orphan Drug Designation for INFRADURE to treat hepatitis D

Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that it has filed for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for INFRADURE for the treatment of hepatitis D.

23 Apr 2012

RVX-208 molecule increases apolipoprotein A-I production

Resverlogix Corp. today announces the "Mechanism of Action" (MoA) by which RVX-208 increases apolipoprotein A-I (ApoA-I) production.

23 Apr 2012

Drug Trial News

Tolero granted exclusive global rights to commercialize MannKind's novel BTK compounds

Pharmanest commences SHACT Phase I pharmacokinetic study

Only few clinical trials are being conducted to test drugs in pediatric patients

New URMC trial to evaluate carvedilol for high blood pressure

Positive top-line results from Shire’s Vyvanse Phase 2 study on binge eating disorder

CytRx commences INNO-206 Phase 2 clinical trial for pancreatic cancer

First-ever study to evaluate effects of interaction between metamphetamines and Ibudilast

ASIA honors SCI researchers with 2012 Apple Award

Daily ART safe and effective in preventing mother-to-child HIV transmission

Clinical and Translational Science Institute-Children's National awards pilot grant to GW researchers

Positive results from Repligen's RG3039 Phase 1 study for spinal muscular atrophy

Omega-3 supplements do not improve diastolic function in older adults

S-equol effective in reducing menopausal hot flashes, muscle and joint pain among U.S. women

Clinical trial to evaluate IGF-1 in children with SHANK3 deficiency

Biogen Idec announces positive data from oral BG-12 second Phase 3 trial on RRMS

Protein blend intake following resistance exercise may build muscles

Gabapentin drug helps people to quit cannabis

R-Tech Ueno completes RK-023 phase I study on hypotrichosis of the eyelashes

Medgenics seeks FDA Orphan Drug Designation for INFRADURE to treat hepatitis D

RVX-208 molecule increases apolipoprotein A-I production

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News